Clinical Research Directory

Inclusion Criteria: * Patients with aortic stenosis aged 60-85 years. * Successful transfemoral TAVR (per VARC-3 criteria). * Voluntary participation with signed Informed Consent Form. Exclusion Criteria: * Known hypersensitivity, allergy, or documented intolerance to colchicine. * Hematologic abnormalities defined as hemoglobin \<80 g/L or white blood cell count \<4.0 × 10⁹/L at screening. * Severe renal impairment defined as creatinine clearance \<30 mL/min (calculated by the Cockcroft-Gault formula) or serum creatinine \>2 × upper limit of normal (ULN). * Significant hepatic disease, including liver cirrhosis, chronic active hepatitis, hepatic injury (alanine aminotransferase \>3 × ULN or total bilirubin \>2 × ULN), or cholestasis. * Known history of bone marrow suppression. * Concomitant use of strong CYP3A4 or P-glycoprotein (P-gp) inhibitors, including but not limited to cyclosporine, amiodarone, clarithromycin, erythromycin, omeprazole, or verapamil. * Concomitant use of strong CYP3A4 or P-glycoprotein (P-gp) inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, or rifampin. * Known neuromuscular disorders or creatine kinase (CK) \>3 × ULN at screening. * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea. * Active malignancy or history of cancer. * Current use of systemic corticosteroids (oral or intravenous) or systemic immunosuppressive agents (topical or inhaled corticosteroids permitted). * Acute inflammatory condition or active viral infection at the time of enrollment. * Known galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. * Estimated life expectancy \<1 year as determined by the investigator.